

REMARKS

Claim Amendments

The claims have been amended to eliminate improper multiple dependencies and to otherwise place the claims in a format more in accordance with customary US practice.

Specifically:

- Claim 1 has been amended to make minor formal corrections.
- Claim 3 and 4 have been amended to make them dependent on claim 1 only so as to eliminate improper multiple dependency in later multiple dependent composition and method claims.
- Claim 5 has been cancelled as being in a “use” format not generally acceptable under US practice.
- Claim 6 has been amended to remove the unnecessary word “optionally” and to expand its dependency to include new compound claims 11 and 12.
- Claim 7 has been amended to expand its dependency to include new compound claims 11 and 12.
- Claims 8 and 9 have been cancelled as being in a “use” format not generally acceptable under US practice.
- Claim 10 has been amended to be dependent only on claim 1; to remove the reference to “preferably bromo or iodo” as not further limiting the claim; and to replace the subjective terms “where desired or necessary” and “where desired” with “optionally.”
- New compound claim 11 is dependent on claim 1 and limits the claim 1 definition of R² to an optionally substituted five-membered heteroaromatic ring containing 1 to 4 heteroatoms independently selected from O, S and N.
- New compound claim 12 is dependent on claim 1 and recites nine specifically exemplified compounds, or a pharmaceutically acceptable salt thereof.
- New method claims 13 and 14 have been added.

Support for new claim 11 is found in original claim 1 and throughout the specification.

Support for new claim 12 is specifically found in Examples 11, 15, 31, 32, 34, 36, 46, 94 and 95.

Support for new method claim 13 is found throughout the specification and more specifically at page 34, lines 24-29. Support for new method claim 14 is found throughout the specification and more specifically at page 34, line 31 to page 35, line 3. Support for the term "prophylaxis" is found, *inter alia*, at page 35, lines 5-10.

No new matter is added by these amendments. Therefore, entry of these amendments is believed to be in order and is respectfully requested prior to issuing a first Action on the merits in this application.

Following entry of the above amendments, claims 1-4, 6, 7 and 10-14 are pending in this application.


Information Disclosure Statement

The Examiner's attention is called to the Information Disclosure Statements and accompanying forms PTO-1449 that were submitted in this application at the time of entry into the US National Stage on March 26, 2006 and on November 8, 2006, together with each listed document except US Patents and US published applications. It is respectfully requested that the Examiner consider each of these documents prior to the first Action on the merits, and initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit

Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: January 8, 2007
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001